Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.
You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings
Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We’re driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.
In view of our vision of a world free of pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.
We follow a holistic and solution-agnostic approach to deliver highly effective pain treatments, building our programmes on a firm foundation of human pathophysiology and solid human target validation.
Ambition is welcome at Grünenthal. Whether you’re a world-class scientist or a talented graduate, together we drive cutting-edge research projects and develop products of the future. Grünenthal offers a culture of opportunity. Join us!
Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.
Grünenthal considers the outbreak and spread of Covid-19 to be a serious situation and fully recognises its responsibilities related to safeguarding the well-being and safety of our employees, ensuring an uninterrupted supply of our medicines for patients, and supporting communities with curbing the Covid-19 outbreak.
Grünenthal issued notice to the European Commission (EC) and the European Medicines Agency (EMA) to withdraw Zurampic® (lesinurad)1 and Duzallo® (lesinurad and allopurinol, currently not marketed)2 for the treatment of chronic hyperuricaemia in adults with gout, who have not achieved target serum uric acid levels with an adequate dose of a Xanthine Oxidase Inhibitor (XOI) alone, from the market in Europe. Zurampic and Duzallo will not be marketed in Latin America.
The German federal parliament adopted an amendment to the Contergan Foundation Act on 19 June 2020, whereby benefits to thalidomide victims, once granted, cannot be revoked. This includes the thalidomide pension, which is paid by the Contergan Foundation. Only in special cases, such as deliberate deception, is it possible to withdraw benefits.
Grünenthal decided to discontinue its two ongoing Phase III clinical trials of Neridronate (KF7013-02 and KF7013-04) in patients with Complex Regional Pain Syndrome (CRPS). The clinical development program had foreseen to randomize 360 people with CRPS in these trials.